Neoantigen vaccine: an emerging tumor immunotherapy

Genetic instability of tumor cells often leads to the occurrence of a large number of mutations, and expression of non-synonymous mutations can produce tumor-specific antigens called neoantigens. Neoantigens are highly immunogenic as they are not expressed in normal tissues. They can activate CD4+ and CD8+ T cells to generate immune response and have the potential to become new targets of tumor immunotherapy. The development of bioinformatics technology has accelerated the identification of neoantigens. The combination of different algorithms to identify and predict the affinity of neoantigens to major histocompatibility complexes (MHCs) or the immunogenicity of neoantigens is mainly based on the whole-exome…

• NN
  National Natural Science Foundation of China

  Awards: 81702907, 81872278, 2018SK21210, 2018JJ3815, 81672683, 81803025, 81772928, 81672993, 81572787, 81772901, 81572787, 81672683, 81672993, 81672688, 81702907, 81772901, 81772928, 81803025 and 81872278, 81672688, 2018SK21211, 2018JJ3704, 111-2-12
• NS
  Natural Science Foundation of Hunan Province

  Award: 2016JC2035, 2017SK2105, 2018JJ3704, 2018JJ3815, 2018SK21210 and 2018SK21211
• HE
  Higher Education Discipline Innovation Project

  Awards: 111-2, 111-2-12
• OE
  Overseas Expertise Introduction Project for Discipline Innovation

  Awards: No. 111-2-12, 111 Project, No. 111–2-12, 111 Project, 111-2-12, 111 Project, No. 111-2-12